New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2013
16:18 EDTVNDAVanda withdraws Marketing Authorization Application for Fanaptum in EU
Vanda Pharmaceuticals announced that it has withdrawn its Marketing Authorization Application submitted to the European Medicines Agency's Committee for Medicinal Products for Human Use for Fanaptum for the treatment of adult patients with schizophrenia. This withdrawal is based on a request by the CHMP/Rapporteur/Co-rapporteur for Vanda to submit the results from an ongoing relapse prevention, randomized iloperidone-placebo withdrawal study in patients with schizophrenia. The results of this study will not be available in the timeframe allowed in the Centralised Procedure. Vanda intends to reassess its European regulatory strategy for Fanaptum once the results from the Relapse Prevention Study in Patients with Schizophrenia become available.
News For VNDA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
10:37 EDTVNDAOptions with decreasing implied volatility
Options with decreasing implied volatility: FUEL GREK NLNK HLSS SLXP LL VNDA AWAY DWA TRUE
February 24, 2015
10:08 EDTVNDAOptions with decreasing implied volatility
Subscribe for More Information
February 23, 2015
10:17 EDTVNDAOptions with decreasing implied volatility
Subscribe for More Information
February 19, 2015
09:12 EDTVNDAOn The Fly: Pre-market Movers
Subscribe for More Information
07:09 EDTVNDAVanda sees FY15 sales of Hetlioz and Fanapt $95M-$110M
Subscribe for More Information
07:08 EDTVNDAVanda reports Q4 adjusted EPS (36c), two estimates (20c)
Reports Q4 revenue $15.37M, two estimates $16.15M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use